Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases. News about VTVT frequently centers on the development of its lead program, cadisegliatin (TTP399), a novel liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for people with type 1 diabetes.
Company updates often cover key milestones in the CATT1 Phase 3 trial of cadisegliatin in adults with type 1 diabetes, including trial initiation, randomization of the first study participant, and expectations for topline data. vTv Therapeutics also issues news on its Phase 2 clinical study protocol for cadisegliatin as an adjunctive therapy to insulin in people with type 2 diabetes, developed in collaboration with M42’s Insights Research Organization & Solutions (IROS) for sites in the United Arab Emirates, Jordan, and Tunisia.
Investors following VTVT news can expect regular clinical development updates, such as preclinical and clinical data presentations at scientific meetings, including the INNODIA Symposium at the European Association for the Study of Diabetes Annual Meeting. The company also reports on intellectual property developments, including U.S. patent allowances for crystalline forms of cadisegliatin with patent terms running through 2041.
Another recurring theme in vTv Therapeutics news is financing and corporate activity, such as private placements with healthcare institutional investors and the T1D Fund intended to support the CATT1 Phase 3 trial and broader cadisegliatin program. Updates on participation in investor conferences and changes to scientific advisory structures also appear in the news flow.
For readers tracking VTVT stock, this news page aggregates company press releases and related coverage so they can monitor progress in clinical trials, regulatory interactions, patent protection, and capital-raising efforts tied to vTv Therapeutics’ diabetes-focused pipeline.
vTv Therapeutics (Nasdaq: VTVT) said its management team will participate in a fireside chat and hold 1x1 investor meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026.
The fireside chat is scheduled for March 23, 2026 at 10:00 AM PDT and will be webcast live with a replay available on the company website.
vTv Therapeutics (Nasdaq: VTVT) reported Q4 and full-year 2025 results and provided a corporate update on March 10, 2026. Cash was $88.9M at year-end; the company received $20.0M upfront from Newsoara in Feb 2026 under an amended license for HPP737. Enrollment in the Phase 3 CATT1 trial is expected to complete in Q3 2026.
Full-year 2025 net loss was $27.0M ($3.20 per share); R&D spend rose to $17.9M driven by cadisegliatin clinical activity.
vTv Therapeutics (Nasdaq: VTVT) said management will participate in two investor conferences in late February and early March 2026. Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 26, 2026, 11:20 AM ET, virtual, presentation only) and TD Cowen 46th Annual Health Care Conference (Mar 3, 2026, 9:50 AM ET, Boston, presentation and 1x1 meetings). Webcasts will be available for both events per the company.
vTv Therapeutics (Nasdaq: VTVT) amended its license with Newsoara to grant an exclusive worldwide license to develop and commercialize PDE4 inhibitor HPP737. vTv will receive a $20 million upfront payment, up to ~$50 million in development milestones, up to $65 million in sales milestones, and tiered royalties.
vTv continues to advance cadisegliatin in its ongoing Phase 3 CATT1 trial while leveraging the Newsoara collaboration to monetize and de-risk HPP737 globally.
vTv Therapeutics (Nasdaq: VTVT) submitted a Phase 2 clinical study protocol for cadisegliatin to the Abu Dhabi Department of Health in collaboration with M42’s IROS.
The double-blind, randomized, placebo-controlled trial will be the longest cadisegliatin study to date: a 12-month trial enrolling approximately 300 insulin-treated type 2 diabetes patients across UAE, Jordan, and Tunisia, with three arms (400 mg once daily, 800 mg once daily, and placebo). The first patient first visit is expected in Q1 2026. vTv is the regulatory sponsor and M42 is funding the study.
vTv Therapeutics (Nasdaq: VTVT) reported Q3 2025 results and operational updates on Nov 6, 2025. Key developments include randomizing the first patient in the Phase 3 CATT1 trial (Aug 2025) and expecting topline CATT1 data in H2 2026. The company completed an $80 million private placement (Sep 2025) to fund CATT1 and program development. Cash was $98.5 million at September 30, 2025 versus $36.7 million at December 31, 2024. R&D expense for Q3 2025 was $7.0 million (Q3 2024: $3.2M); G&A was $3.7 million (Q3 2024: $3.3M). Q3 net loss attributable to vTv shareholders was $8.7 million or $1.08 per basic share. A U.S. patent covering crystalline salts and co-crystals of cadisegliatin was allowed with exclusivity expected through 2041.
vTv Therapeutics (Nasdaq: VTVT) announced on October 9, 2025 the appointment of Alfonso Galderisi, Mark Evans, Chantal Mathieu, and Klara Klein to its Scientific Advisory Board. The SAB, composed of international leaders in endocrinology, clinical trial design, and regulatory science, will advise on the development of cadisegliatin, an oral adjunctive therapy currently being investigated in Phase 3 clinical trials for type 1 diabetes (T1D).
The board complements existing members, including John Buse and Alexander Fleming, to provide input on clinical trial planning, study design, endpoints, regulatory strategy, and target product profile for cadisegliatin.
vTv Therapeutics (Nasdaq: VTVT) announced its participation in the INNODIA Symposium at the EASD 61st Annual Meeting, where it will present research on two investigational small molecules for type 1 diabetes (T1D). Dr. Carmen Valcarce, EVP and CSO, will present new preclinical data on TTP-RA, an oral RAGE antagonist being evaluated for T1D prevention in combination with an anti-CD3 antibody.
The presentation will include data demonstrating TTP-RA's ability to restore glucose homeostasis and modulate immune responses. Additionally, updates will be shared on cadisegliatin, their first-in-class oral glucokinase activator currently in Phase 3 trials (CATT1) as an adjunctive therapy for T1D. The company is actively seeking strategic partnerships to advance TTP-RA development.
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9 for one-on-one investor meetings, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, where management will participate in a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9, participating in one-on-one investor meetings. On the same day, management will also present at the Morgan Stanley 23rd Annual Global Healthcare Conference, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.